RNAC insider trading
NasdaqGM HealthcareCartesian Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Company website: www.cartesiantherapeutics.com
RNAC insider activity at a glance
FilingIQ has scored 211 insider transactions for RNAC since Nov 13, 2023. The most recent filing in our index is dated Apr 2, 2026.
Across the full history, 52 open-market purchases
and 32 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RNAC insider trades is 58.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RNAC Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RNAC?
- FilingIQ tracks 211 Form 4 insider transactions for RNAC (Cartesian Therapeutics, Inc.), covering filings from Nov 13, 2023 onwards. 5 of those were filed in the last 90 days.
- Are RNAC insiders net buyers or net sellers?
- Across the full Form 4 history for RNAC, 52 transactions (25%) were open-market purchases and 32 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RNAC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RNAC in?
- Cartesian Therapeutics, Inc. (RNAC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $161.17M.
Methodology & sources
Every RNAC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.